title: Mucosal vaccine delivery by non-recombinant spores of Bacillus subtilis.
abstract: Development of mucosal vaccines strongly relies on an efficient delivery system and, over the years, a variety of approaches based on phages, bacteria or synthetic nanoparticles have been proposed to display and deliver antigens. The spore of Bacillus subtilis displaying heterologous antigens has also been considered as a mucosal vaccine vehicle, and shown able to conjugate some advantages of live microrganisms with some of synthetic nanoparticles. Here we review the use of non-recombinant spores of B. subtilis as a delivery system for mucosal immunizations. The non-recombinant display is based on the adsorption of heterologous molecules on the spore surface without the need of genetic manipulations, thus avoiding all concerns about the use and environmental release of genetically modified microorganisms. In addition, adsorbed molecules are stabilized and protected by the interaction with the spore, suggesting that this system could reduce the rapid degradation of the antigen, often observed with other delivery systems and identified as a major drawback of mucosal vaccines.
authors.forename: Ezio
authors.initials: E
authors.lastname: Ricca
authors.forename: Loredana
authors.initials: L
authors.lastname: Baccigalupi
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Cangiano
authors.forename: Maurilio
authors.initials: M
authors.lastname: De Felice
authors.forename: Rachele
authors.initials: R
authors.lastname: Isticato
mesh_terms: D058956:Administration, Mucosal; D001412:Bacillus subtilis / Q000378:metabolism*; D016503:Drug Delivery Systems; D008954:Models, Biological; D011995:Recombination, Genetic / Q000235:genetics; D013171:Spores, Bacterial
references.citation: Vaccine. 2004 Mar 12;22(9-10):1177-87
references.pmid: 15003646
references.citation: Nat Rev Microbiol. 2010 Dec;8(12):890-6
references.pmid: 20972452
references.citation: Nat Nanotechnol. 2014 Feb;9(2):137-41
references.pmid: 24463362
references.citation: FEMS Microbiol Rev. 2012 Jan;36(1):131-48
references.pmid: 22091839
references.citation: Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):226-30
references.pmid: 8552610
references.citation: Microb Cell Fact. 2013 Oct 29;12:98
references.pmid: 24168229
references.citation: Int Immunol. 2001 Apr;13(4):541-51
references.pmid: 11282993
references.citation: Cell Mol Life Sci. 2002 Mar;59(3):410-6
references.pmid: 11964119
references.citation: Infect Immun. 2000 Jun;68(6):3097-102
references.pmid: 10816449
references.citation: J Appl Microbiol. 2008 Dec;105(6):2178-86
references.pmid: 19120663
references.citation: Biotechnol Appl Biochem. 2015 Mar-Apr;62(2):237-44
references.pmid: 24934149
references.citation: Infect Immun. 2003 May;71(5):2810-8
references.pmid: 12704155
references.citation: J Immunol. 2004 Jan 15;172(2):1118-24
references.pmid: 14707086
references.citation: Vaccine. 2012 May 9;30(22):3266-77
references.pmid: 22446640
references.citation: Adv Drug Deliv Rev. 2006 Apr 20;58(1):52-67
references.pmid: 16516335
references.citation: Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3007-9
references.pmid: 12631692
references.citation: Appl Environ Microbiol. 2002 May;68(5):2344-52
references.pmid: 11976107
references.citation: Nat Rev Microbiol. 2013 Jan;11(1):33-44
references.pmid: 23202530
references.citation: Int Rev Immunol. 2009;28(6):487-505
references.pmid: 19954360
references.citation: Clin Vaccine Immunol. 2011 Dec;18(12):2168-77
references.pmid: 22030372
references.citation: Vaccine. 2010 Jan 22;28(4):1021-30
references.pmid: 19914191
references.citation: Biophys J. 2005 Jan;88(1):603-8
references.pmid: 15501940
references.citation: Microb Cell Fact. 2012 Aug 03;11:100
references.pmid: 22863452
references.citation: Annu Rev Biomed Eng. 2012;14:17-46
references.pmid: 22524387
references.citation: Infect Immun. 2013 Nov;81(11):4071-80
references.pmid: 23959722
references.citation: Mol Cell. 2008 Aug 8;31(3):406-14
references.pmid: 18691972
references.citation: J Bacteriol. 2001 Nov;183(21):6294-301
references.pmid: 11591673
references.citation: Colloids Surf B Biointerfaces. 2014 Apr 1;116:568-75
references.pmid: 24583259
references.citation: Microb Cell Fact. 2006 Jun 23;5:23
references.pmid: 16796731
references.citation: Cell Host Microbe. 2007 Jun 14;1(4):299-308
references.pmid: 18005709
references.citation: Food Microbiol. 2011 Apr;28(2):214-20
references.pmid: 21315976
references.citation: J Phys Chem B. 2008 Feb 21;112(7):2233-44
references.pmid: 18247596
references.citation: Vaccine. 2007 Jan 15;25(5):788-93
references.pmid: 17028079
references.citation: Microb Cell Fact. 2014 Feb 24;13(1):30
references.pmid: 24568122
references.citation: Res Microbiol. 2006 Nov;157(9):891-7
references.pmid: 17005378
references.citation: Microbiology (Reading). 2009 Feb;155(Pt 2):338-346
references.pmid: 19202083
references.citation: Infect Immun. 2000 Feb;68(2):760-6
references.pmid: 10639444
references.citation: J Drug Target. 2013 Jul;21(6):528-41
references.pmid: 23480726
references.citation: J Mol Recognit. 2007 Nov-Dec;20(6):483-9
references.pmid: 17932994
references.citation: Vaccine. 2004 May 7;22(15-16):1873-85
references.pmid: 15121298
references.citation: Res Microbiol. 2009 Jul-Aug;160(6):375-9
references.pmid: 19589385